Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors

WEI-ZEN SUNLin, Han-WeiHan-WeiLinWAN-YU CHENCHUNG-LIANG CHIENYEN-LING LAIJUNG CHENYU-LI CHENWEN-FANG CHENG2023-09-082023-09-082023-072051-1426https://scholars.lib.ntu.edu.tw/handle/123456789/635233Expression of immune checkpoints in the tumor microenvironment is one mechanism underlying paclitaxel (PTX) chemoresistance. This study aimed to investigate whether the addition of checkpoint blockade to PTX can improve the therapeutic efficacy against apparently disseminated intraperitoneal tumors.enB-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Immune Checkpoint Inhibitors; Immunomodulation[SDGs]SDG3Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumorsjournal article10.1136/jitc-2023-006694374637892-s2.0-85165520894https://api.elsevier.com/content/abstract/scopus_id/85165520894